Decoy Therapeutics is expected to report a Q2 2026 consensus loss of $2.88 per share on $0 revenue, with the stock currently trading at $3.92, significantly below the average analyst price target of $30.00.
Investors are primarily focused on clinical milestone updates for D-MAV, the company's lead multi-antiviral candidate, and the timing of its upcoming IND filing. The company recently completed a 1-for-12 reverse stock split in March 2026 to maintain its Nasdaq listing while transitioning its focus toward AI-driven peptide conjugates. Management's commentary regarding the cash runway and R&D spending efficiency will be critical as the firm prepares for first-in-human clinical trials.